Volume 10, supplement issue 2, December 2014
Canadian Society of Allergy and Clinical Immunology and AllerGen Abstracts 2014
60 articles in this issue
-
-
Epinephrine auto injector administration by parents or patients for anaphylaxis during supervised oral food challenges and assessment of confidence
Authors (first, second and last of 9)
-
C-CARE: comparing three years of anaphylaxis in children treated at the Montreal Children’s Hospital
Authors (first, second and last of 9)
-
Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
Authors (first, second and last of 8)
-
-
Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
Authors (first, second and last of 8)
-
-
-
-
-
-
-
The prophylactic use of C1 esterase inhibitor in HAE patients undergoing invasive procedures
Authors (first, second and last of 5)
-
Efficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children
Authors (first, second and last of 9)
-
-
-
Anti-Ige monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review
Authors (first, second and last of 6)
-
Penicillin allergies: referral and management practices of anesthesiologists
Authors (first, second and last of 5)
-
-
-
-
Anti-Ige monoclonal antibody therapy for the treatment of patients with chronic rhinosinusitis: a multi-disciplinary practice review
Authors (first, second and last of 4)
-
-
B cell Semaphorin 4c expression mitigates the airway hyperresponsiveness and acute inflammation which characterize allergic airway disease
Authors (first, second and last of 5)
-
The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
Authors (first, second and last of 4)
-
Value of skin testing children with a family history of food allergy before ingestion of suspect food allergens
Authors (first, second and last of 5)
-
-
Efficacy of short-ragweed sublingual immunotherapy tablet MK-3641 in monosensitized and polysensitized subjects
Authors (first, second and last of 5)
-
The effect of the ragweed sublingual immunotherapy tablet MK-3641 on rescue medication use
Authors (first, second and last of 8)
-
Magnitude of changes in patient symptom and medication scores in grass allergy immunotherapy trials: dependency on levels of pollen exposure
Authors (first, second and last of 8)
-
Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
Authors (first, second and last of 7)
-
-
-
-
Reconciliation of health records following penicillin allergy testing of hospitalized patients
Authors (first, second and last of 4)
-
A case of acquired angioedema associated with Waldenstrom’s macroglobulinemia treated with rituximab
Authors (first, second and last of 4)
-
-
-
-
-
-
-
-
Proteinase-activated receptor-2 (PAR-2) expression on inflammatory cells in severe asthma
Authors (first, second and last of 9)
-
Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
Authors (first, second and last of 6)
-
Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status
Authors (first, second and last of 11)
-
-
Impact of air pollution on physician office visits for common childhood conditions in Ontario, Canada
Authors (first, second and last of 5)
-
Tobacco smoke induces changes in IL-1 family in bronchial epithelial cells obtained from asthmatic individuals
Authors (first, second and last of 7)
-
Lineage specific role of Ship1 in development of allergic airway inflammation
Authors (first, second and last of 5)
